Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
about
The promise of neuroprotective agents in Parkinson's diseaseThe role of oxidative stress in Parkinson's diseaseClinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson diseaseEffects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.Medical management of Parkinson's disease: focus on neuroprotectionPresent and future drug treatment for Parkinson's disease.Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.Rasagiline in the pharmacotherapy of Parkinson's disease--a review.Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.Zydis selegiline in the management of Parkinson's disease.Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors.Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.Progress in neuroprotection in Parkinson's disease.Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Mitochondrial proteomics as a selective tool for unraveling Parkinson's disease pathogenesis.Pharmacological therapy in Parkinson's disease: focus on neuroprotection.Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.Adjunctive therapy in Parkinson's disease: the role of rasagiline.Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy.Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets.Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.Role of rasagiline in treating Parkinson's disease: Effect on disease progression.Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.Client perception of therapeutic factors in group psychotherapy and growth groups: an empirically-based hierarchical model.Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
P2860
Q21129436-821E415E-3313-4F54-BBE5-0BA835D3719FQ24307946-03C26B50-3580-4E96-861C-54005F64CF2BQ28262497-20616778-77C7-4A01-9DD7-020A548AB855Q33825775-70D0EF63-DD99-4F67-AB8D-AD8B17474DE9Q35047710-25115A69-4149-4A0B-945F-77D88E1E2946Q35092165-6A5E909D-CAC3-499B-8A79-62C04063F61CQ35484805-9E8A391C-816D-498C-9010-584CA9097946Q35738987-59BD7F73-CD79-4E0E-BA3F-02BB39E997C2Q36273444-4E7DF01F-30D0-407D-9B44-B915F7BCBA78Q36307876-24AEE1DE-B1D8-4899-A494-D07E49E5A28BQ36968199-8A69B723-FD87-48BB-8A0B-8729D7CBADF0Q36983563-B41DFBAD-5257-4868-890D-EFAF0BB8A3BDQ37016034-2EF4FE3D-304E-42AB-A32C-C3A46252952AQ37114112-C8062859-BC12-4E75-BF60-2A729CC84D06Q37578490-3278AF97-30B6-4ACF-8679-9B7A66321AD9Q37727186-A707F530-06F3-4A10-99D2-802FB8B2C589Q37741285-E69798FE-857A-443B-B3C9-D818BF224ABBQ37939755-A3ACC52D-4CDA-4CC7-BA1A-F36CCD61CC10Q37963572-7EE5B957-728E-43E4-A64E-0F1F4493CADFQ38026830-F0A57A20-8F1E-4E01-94E4-6781180528CFQ38112214-90C7C909-7D71-4A46-8BEE-90BABD8EF618Q38156161-9D4CBB7F-C32D-43D1-B967-A8DEF6F794CCQ38414169-F202738B-F0FD-4D91-B89C-85AB0B2BE88CQ38701423-66DA269F-0510-4F7F-B1D1-31B8C896E3CEQ39280910-E80A28E2-D915-4EEE-A12F-846BAE0C652AQ39681299-E2FA7C9D-518A-488B-AFCF-3551A38F4970Q39694072-79A9E0EE-1547-4247-BEFE-A1DACF7DCAFDQ41527937-7F11885B-E0E4-406B-B720-C8A66C4AFC5FQ42399167-DA37DE3F-D553-42AA-86D2-09FE5D1D8AA6Q43073052-98EA6AF5-C6C7-4AC4-90D0-3BCE2DC6AE8CQ43521319-EC759BB1-1BCC-44CC-94A2-B4EE64F29BE4Q46654865-1AF8599C-2F42-455E-B699-C878E8ED3DD4Q47774778-CE637CEC-B0EE-4CFB-BE57-6BC70C9EA9CC
P2860
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
description
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
im Januar 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 30 January 2004)
@en
vedecký článok (publikovaný 2004/01/30)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/01/30)
@nl
наукова стаття, опублікована в січні 2004
@uk
مقالة علمية (نشرت في 30-1-2004)
@ar
name
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@ast
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@en
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@nl
type
label
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@ast
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@en
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@nl
prefLabel
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@ast
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@en
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@nl
P2093
P3181
P1433
P1476
Contrasting neuroprotective an ...... rugs rasagiline and selegiline
@en
P2093
Moussa B H Youdim
Orit Bar Am
Tamar Amit
P304
P3181
P356
10.1016/J.NEULET.2003.10.067
P407
P577
2004-01-30T00:00:00Z